Sandoz Unveils Zero-Profit COVID-19 Portfolio
Dexamethasone On List For Low-Income Countries
Lutz Hegemann, chief operating officer for global health at Novartis, says the project will continue until a vaccine or curative treatments have reached the world's poorest places, not just until they are first approved in a high income country.
You may also be interested in...
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.
Regulators whipsawed by COVID-19-related drug shortages are seeking better ways to forecast demand.
The standout development in this latest Coronavirus Notebook is that the cheap and plentiful steroid dexamethasone has been shown to reduce deaths by a third in ventilated COVID-19 patients in the UK Recovery trial. In other news, there is fresh funding for smaller firms working on potential treatments and vaccines, and a number of organizations have decided to make their research tools and resources available free of charge in return for open publication of any coronavirus-related findings.